Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.

The Journal of clinical investigation - 1 Aug 2010

Mohseni Morassa, Park Ben Ho

Abstract excerpt

Targeted cancer therapeutics can be effective when patients are preselected to maximize the chance of response. Increasingly, molecular markers such as oncogenic DNA mutations are being exploited to help guide patient preselection. These DNA lesions can predict for either a positive or negative response to a given drug. Finding such predictive biomarkers is an ongoing challenge. New work by Di Nicolantonio and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Everolimus
Share to Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 20664174
DOI: 10.1172/JCI44026
PMCID: PMC2912204

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.PMID 20664174Read ↗

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.Semantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Semantic proximity Read ↗

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.Semantic proximity Read ↗

Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CASemantic proximity Read ↗

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor GrowthSemantic proximity Read ↗

Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.Semantic proximity Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.